Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
出版年份 2022 全文链接
标题
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
作者
关键词
-
出版物
CURRENT OPINION IN LIPIDOLOGY
Volume 33, Issue 3, Pages 147-159
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2022-06-13
DOI
10.1097/mol.0000000000000830
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acute coronary syndromes
- (2022) Brian A Bergmark et al. LANCET
- Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
- (2021) Gregory G. Schwartz et al. CIRCULATION
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
- (2021) Glen J. Pearson et al. CANADIAN JOURNAL OF CARDIOLOGY
- Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study
- (2021) Matthew J. Janik et al. ATHEROSCLEROSIS
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- (2021) Gregory G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
- (2020) Peter Sever et al. European Journal of Preventive Cardiology
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- (2020) Nicholas A. Marston et al. CIRCULATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- (2020) Robert P. Giugliano et al. STROKE
- Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
- (2020) Baris Gencer et al. JAMA Cardiology
- PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
- (2020) Gerald F. Watts et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
- (2020) Rafael Diaz et al. European Journal of Preventive Cardiology
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
- (2020) José Tuñón et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
- (2020) Michael Szarek et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
- (2019) Michael B. Boffa et al. Nature Reviews Cardiology
- Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial
- (2019) J. Wouter Jukema et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
- (2019) Sabina A. Murphy et al. JAMA Cardiology
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
- (2019) David M. Charytan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
- (2019) Matthew T. Roe et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
- (2019) Shaun G. Goodman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS)
- (2019) Konstantinos C. Koskinas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
- (2019) Nicholas A. Marston et al. CIRCULATION
- Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial
- (2019) Amy Damask et al. CIRCULATION
- Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
- (2019) Peter R Sinnaeve et al. EUROPEAN HEART JOURNAL
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
- (2019) J. Wouter Jukema et al. CIRCULATION
- Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
- (2018) Marc S. Sabatine et al. CIRCULATION
- PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
- (2018) Mikaël Croyal et al. CLINICAL SCIENCE
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events
- (2018) Michael Szarek et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role
- (2016) Frederick J. Raal et al. JOURNAL OF LIPID RESEARCH
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts
- (2014) A. Laschkolnig et al. CARDIOVASCULAR RESEARCH
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search